Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
14.34 USD | +4.75% | +10.78% | -34.10% |
Apr. 25 | Truist Securities Cuts Sage Therapeutics' Price Target to $18 From $22, Hold Rating Maintained | MT |
Apr. 25 | Transcript : Sage Therapeutics, Inc., Q1 2024 Earnings Call, Apr 25, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.10% | 824M | |
-2.12% | 103B | |
+1.48% | 95.28B | |
+3.00% | 22.15B | |
-16.12% | 21.02B | |
-8.40% | 18.15B | |
-41.01% | 16.73B | |
-14.18% | 16.05B | |
+4.26% | 13.68B | |
+34.79% | 12.17B |
- Stock Market
- Equities
- SAGE Stock
- News Sage Therapeutics, Inc.
- Oppenheimer Adjusts Sage Therapeutics Price Target to $25 From $23, Maintains Perform Rating